News

Scientific publication about the beneficial effect of the prototype SERI WOBE437 in a clinically relevant mouse model of Multiple Sclerosis and transient spasticity

Synendos Therapeutics Raises CHF 20 Million in Series A Financing

Synendos and Prof. Jürg Gertsch received an Innosuisse Innovation Grant (total value of CHF 950’000)

EU reports on the successful SME Instrument Phase 1 grant received by Synendos

Award ceremony Venture Leaders 2019

Synendos won Venture Kick Stage III (CHF 100’000)